A Phase 1 interventional study of Dabigatran etexilate pellets and Dabigatran etexilate powder in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-23.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the relative bioavailability of 150 mg of dabigatran etexilate as pellets on food and of 150 mg of dabigatran etexilate as powder resolved in reconstitution solution, both with 150 mg of dabigatran etexilate as capsule in healthy volunteers
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For female subjects:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Dabigatran etexilate pellets
Drug: Dabigatran etexilate powder
Drug: Dabigatran etexilate capsule
AUC0-inf for Total Dabigatran
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
AUC0-inf for Free Dabigatran
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for free dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Cmax for Total Dabigatran
Maximum measured concentration of the analyte in plasma (Cmax) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Cmax for Free Dabigatran
Maximum measured concentration of the analyte in plasma (Cmax) for free dabigatran
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
AUC0-tz for Total Dabigatran
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
AUC0-tz for Free Dabigatran
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for free dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Tmax for Total Dabigatran
Time from dosing to the maximum concentration of the analyte in plasma (tmax) for total dabigatran
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Tmax for Free Dabigatran
Time from dosing to the maximum concentration of the analyte in plasma (tmax) for free dabigatran
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
λz for Total Dabigatran
Terminal rate constant in plasma (λz) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
λz for Free Dabigatran
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
t1/2 for Total Dabigatran
Terminal half-life of the analyte in plasma (t1/2) for total dabigatran
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
t1/2 for Free Dabigatran
Terminal half-life of the analyte in plasma (t1/2) for free dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
MRTpo for Total Dabigatran
Mean residence time of the analyte in the body after po administration (MRTpo) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
MRTpo for Free Dabigatran
Mean residence time of the analyte in the body after po administration (MRTpo) for free dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
CL/F for Total Dabigatran
Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
CL/F for Free Dabigatran
Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for free dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Vz/F for Total Dabigatran
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for total dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Vz/F for Free Dabigatran
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for free dabigatran.
Time frame: -0:30 hour(h) before drug administration and 0:30h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 3:30h, 4:00h, 6:00h, 8:00h, 12:00h, 24:00h, 36:00h and 48:00h after drug administration.
Percentage of Participants With Findings in Physical Examination, Vital Signs , Pulse Rate (PR)), 12-lead ECG, Clinical Laboratory Tests.
Percentage of participants with findings in Physical examination, Vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG (electrocardiogram), Clinical laboratory tests (haematology, clinical chemistry and urinalysis). Relevant findings or worsening of baseline conditions were reported as Adverse events. There were no clinically relevant finding reported for Physical examination, Vital signs (blood pressure, pulse rate), 12-lead ECG and Clinical laboratory tests.
Time frame: From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.
Percentage of Participants With Drug-related Adverse Events
Percentage of participants with investigator defined drug-releated Adverse events.
Time frame: From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.
Assessment of Tolerability by Investigator.
Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.
Time frame: From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.
| Milestone | A/B/C | A/C/B | B/A/C | B/C/A | C/A/B | C/B/A |
|---|---|---|---|---|---|---|
| Started | 5 | 5 | 5 | 5 | 5 | 5 |
| Completed | 5 | 5 | 5 | 5 | 5 | 5 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for total dabigatran.
| ng(nanogram)*h(hour)/mL(milliliter) | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| AUC0-inf for Total Dabigatran | 599 ± 93.3 | 1050 ± 33.8 | 928 ± 32.8 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf) for free dabigatran.
| ng*h/mL | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| AUC0-inf for Free Dabigatran | 464 ± 97.3 | 815 ± 40 | 734 ± 38.2 |
Maximum measured concentration of the analyte in plasma (Cmax) for total dabigatran.
| ng/mL | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Cmax for Total Dabigatran | 74.6 ± 110 | 139 ± 37.8 | 124 ± 37 |
Maximum measured concentration of the analyte in plasma (Cmax) for free dabigatran
| ng/mL | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Cmax for Free Dabigatran | 61.5 ± 110 | 112 ± 40.4 | 103 ± 40.7 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for total dabigatran.
| ng*h/mL | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| AUC0-tz for Total Dabigatran | 565 ± 106 | 1030 ± 34.2 | 908 ± 33.5 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for free dabigatran.
| ng*h/mL | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| AUC0-tz for Free Dabigatran | 436 ± 110 | 794 ± 41.3 | 715 ± 39.5 |
Time from dosing to the maximum concentration of the analyte in plasma (tmax) for total dabigatran
| hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Tmax for Total Dabigatran | 2.0 (1.5 to 6.0) | 1.5 (1.0 to 3.0) | 1.5 (1.0 to 2.5) |
Time from dosing to the maximum concentration of the analyte in plasma (tmax) for free dabigatran
| hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Tmax for Free Dabigatran | 2.0 (1.5 to 6.0) | 1.51 (1.0 to 3.0) | 1.5 (1.0 to 2.0) |
Terminal rate constant in plasma (λz) for total dabigatran.
| 1/hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| λz for Total Dabigatran | 0.079 ± 13.5 | 0.074 ± 14.5 | 0.0756 ± 16.4 |
| 1/hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| λz for Free Dabigatran | 0.091 ± 16 | 0.0811 ± 18.6 | 0.0893 ± 15.7 |
Terminal half-life of the analyte in plasma (t1/2) for total dabigatran
| hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| t1/2 for Total Dabigatran | 8.77 ± 13.5 | 9.37 ± 14.5 | 9.16 ± 16.4 |
Terminal half-life of the analyte in plasma (t1/2) for free dabigatran.
| hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| t1/2 for Free Dabigatran | 7.62 ± 16 | 8.54 ± 18.6 | 7.76 ± 15.7 |
Mean residence time of the analyte in the body after po administration (MRTpo) for total dabigatran.
| hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| MRTpo for Total Dabigatran | 10.8 ± 12 | 10.1 ± 11.4 | 10 ± 12.2 |
Mean residence time of the analyte in the body after po administration (MRTpo) for free dabigatran.
| hour | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| MRTpo for Free Dabigatran | 9.9 ± 14.0 | 9.58 ± 14.1 | 9.15 ± 12.2 |
Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for total dabigatran.
| mL (milliliter)/min (minute) | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| CL/F for Total Dabigatran | 3130 ± 93.3 | 1790 ± 33.8 | 2020 ± 32.8 |
Apparent clearance of the analyte in plasma following extravascular administration (CL/F) for free dabigatran.
| mL (milliliter)/min (minute) | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| CL/F for Free Dabigatran | 4040 ± 97.3 | 2310 ± 40 | 2560 ± 38.2 |
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for total dabigatran.
| Liter | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Vz/F for Total Dabigatran | 2380 ± 92.8 | 1450 ± 35 | 1610 ± 35.9 |
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F) for free dabigatran.
| Liter | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Vz/F for Free Dabigatran | 2670 ± 91 | 1700 ± 41.4 | 1720 ± 37.6 |
Percentage of participants with findings in Physical examination, Vital signs (blood pressure (BP), pulse rate (PR)), 12-lead ECG (electrocardiogram), Clinical laboratory tests (haematology, clinical chemistry and urinalysis). Relevant findings or worsening of baseline conditions were reported as Adverse events. There were no clinically relevant finding reported for Physical examination, Vital signs (blood pressure, pulse rate), 12-lead ECG and Clinical laboratory tests.
| Percentage of participants | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Percentage of Participants With Findings in Physical Examination, Vital Signs , Pulse Rate (PR)), 12-lead ECG, Clinical Laboratory Tests. | 0.0 | 0.0 | 0.0 |
Percentage of participants with investigator defined drug-releated Adverse events.
| Percentage of participants | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Percentage of Participants With Drug-related Adverse Events | 6.7 | 23.3 | 26.7 |
Tolerability will be assessed by the investigator according to the categories good, satisfactory, not satisfactory and bad.
| Percentage of Participants | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| Good | 100.0 | 100.0 | 100.0 |
| Satisfactory | 0.0 | 0.0 | 0.0 |
| Not satisfactory | 0.0 | 0.0 | 0.0 |
| Bad | 0.0 | 0.0 | 0.0 |
| Not assessable | 0.0 | 0.0 | 0.0 |
Collected over From first drug administration until 7 days after the last drug administration of Dabigatran, ie., up to 10 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate 150 mg Capsule: Reference (A) | — | 0/30 (0%) | 2/30 (6.7%) |
| Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | — | 0/30 (0%) | 7/30 (23.3%) |
| Dabigatran Etexilate 150 mg Powder: Test 2 (C) | — | 0/30 (0%) | 8/30 (26.7%) |
| Event | Dabigatran Etexilate 150 mg Capsule: Reference (A) | Dabigatran Etexilate 150 mg Pellets: Test 1 (B) | Dabigatran Etexilate 150 mg Powder: Test 2 (C) |
|---|---|---|---|
| HeadacheNervous system disorders | 2/30 | 5/30 | 8/30 |
| Abdominal pain upperGastrointestinal disorders | 0/30 | 2/30 | 0/30 |
Treated set (TS): This subject set included all subjects who were dispensed trial medication and were documented to have taken at least one dose of investigational treatment. This set was used for safety analysis.
| Age, Continuous(Years) | Overall |
|---|---|
| Mean | 39.8 ± 8.2 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 10 |
| Male | 20 |
No study locations are listed for this record.
The record gives a start of Mar 2009 and a primary completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 7 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran